
Lockheed vs General Dynamics: Who's the Stronger Defense Player?
While Lockheed is well-known for its combat-proven fighter jets like F-35, missile defense systems, and space assets, General Dynamics' portfolio spans commercial and defense aerospace, nuclear submarines and mission-critical IT services.
As nations worldwide are actively striving to modernize their military fleets, enhance deterrence, and secure digital infrastructure, both LMT and GD stand to benefit from the virtue of their scale, contracts and strategic positioning. Thus, for investors seeking exposure to the booming defense industry, choosing between these two stocks might be a challenge, as each brings distinct strengths to the field of long-term investing. To overcome this challenge, let's dig deeper into the fundamental growth drivers, financial strength and risks (if any) of investing in these stocks.
Financial Stability & Growth Drivers: LMT vs GD
Lockheed 's balance sheet shows weak solvency, with just $1.29 billion in cash against $3.12 billion in current debt and $18.52 billion in long-term debt as of June 29, 2025. Despite this, its strong operating cash flow of $1.61 billion in the first half of 2025 enabled generous shareholder returns. The company paid $1.57 billion in dividends, up 2.3% year over year, and repurchased 2.7 million shares worth $1.3 billion. While these moves reflect LMT's strong commitment to shareholders, its high debt relative to cash raises concerns about the long-term sustainability of such payouts.
On the other hand, General Dynamics held $1.52 billion in cash versus $1.20 billion in current debt, as of June 29, 2025. This reflects the company's strong short-term solvency and capacity to invest in product innovation, thereby promoting its long-term growth value.
GD's operating cash flow surged a solid 170.5% year over year to $1.45 billion in the first half of 2025, supporting its shareholder-friendly moves. The company paid $785 million in dividends, as of June 29, up 4.7% from the prior-year level, and repurchased 2.4 million shares. This strong cash position and improved cash flow underscore GD's financial strength and commitment to long-term shareholder value.
A key growth driver for both Lockheed and General Dynamics is the expansionary U.S. defense budget. In May 2025, the White House proposed a 13% hike in defense spending to $1.01 trillion for fiscal 2026. This includes $25 billion for the proposed Golden Dome missile defense system and $40 billion for the U.S. Space Force. Lockheed, a leader in missile defense and space systems, is well-positioned to benefit from this. The proposal also earmarks increased funding for naval shipbuilding and $15.1 billion for cybersecurity — both areas where General Dynamics has a strong presence.
Beyond the defense budget, General Dynamics gains additional momentum from its commercial aviation segment, particularly business jets. With global air traffic steadily rising, demand for GD-built jets like G700 aircraft is rising, boosting long-term revenue prospects.
On the contrary, Lockheed's growth is supported by its innovative defense programs. The company is set to benefit from continued F-35 sustainment, increased PAC-3 missile production, growing demand for HIMARS and GMLRS systems, and modernization of the Trident II D5 ballistic missile. These programs reinforce Lockheed's position as the largest defense contractor in the United States and support its long-term outlook.
Risks of Investing in LMT vs GD
Both Lockheed and General Dynamics face industry-wide challenges such as skilled labor shortages and critical parts scarcity due to ongoing global supply-chain issues. These have been further worsened by the recent U.S. tariffs on imports, including a 25% duty on steel and aluminum from most trade partners, risking limited availability of key aircraft materials and potential production delays for both stocks.
Beyond these common industry headwinds, LMT and GD also face company-specific challenges. Lockheed has encountered performance setbacks on certain classified contracts, resulting in occasional reach-forward losses in recent quarters. In contrast, General Dynamics, with exposure to the commercial aviation sector, is more vulnerable to supply disruptions than Lockheed. While both commercial and defense aerospace face component shortages, the impact is harsher on commercial aerospace due to its reliance on global supply chains and market volatility. The defense segment remains more resilient, backed by consistent government funding, providing some cushion against these industry headwinds.
How Do Zacks Estimates Compare for LMT & GD?
The Zacks Consensus Estimate for Lockheed's 2025 sales suggests a rise of 4.6% from the year-ago quarter's reported figure, while that for its earnings per share (EPS) implies a decline of 4.5%. The stock's near-term bottom-line estimates have moved south over the past 60 days.
The Zacks Consensus Estimate for General Dynamics' 2025 sales implies a year-over-year improvement of 5.9%, while that for its EPS suggests a 9.9% rise. Bottom-line estimates for 2025 and 2026 have moved north over the past 60 days, while the same for the third and fourth quarter of 2025 have gone down.
Stock Price Performance: LMT vs GD
LMT (down 11.7%) has underperformed GD (up 15.5%) over the past three months and has done the same in the past year. Shares of LMT have lost 19.8%, while those of GD have gained 8.2% over the past year.
Valuation of LMT More Attractive Than That of GD
LMT is trading at a forward earnings multiple of 14.69X, below GD's 19.60X.
Image Source: Zacks Investment Research
LMT's ROE Better Than GD
A comparative analysis of both these stocks' Return on Equity (ROE) suggests that GD is less efficient at generating profits from its equity base than LMT.
Image Source: Zacks Investment Research
LMT More Leveraged than GD
A comparative analysis of both these stocks' long-term debt-to-capital ratios implies that GD is less leveraged than LMT.
Final Call
Both Lockheed and General Dynamics stand to benefit amid rising global defense budgets and heightened geopolitical risks.
While Lockheed boasts a robust defense portfolio and competitive valuation, its elevated debt levels and recent market underperformance raise caution, particularly in a fragile economic environment. On the other hand, General Dynamics appears better positioned in the near term, supported by stronger recent earnings, lower leverage, solid cash flow and a more stable stock performance.
Although both stocks hold a Zacks Rank #3 (Hold) at present, General Dynamics' balanced exposure, financial resilience and operational momentum make it the safer and more attractive defense contender at present.
You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
33 minutes ago
- Globe and Mail
SIS, LLC Announces Successful Go-Live of CRB on Microsoft Dynamics 365 and SIS Construct 365 Project Cost Management
DULUTH, Ga., Aug. 6, 2025 /CNW/ -- SIS, LLC, a Microsoft Solutions Partner for Business Applications and leading implementer of ERP and CRM solutions for the construction industry, is thrilled to announce the successful go-live of CRB Group on Microsoft Dynamics 365 (D365) and SIS Construct 365 Project Cost Management (PCM) solution. This milestone marks a significant step in CRB's digital transformation journey, empowering their teams with cutting-edge tools to drive efficiency, profitability, and growth.


CBC
34 minutes ago
- CBC
Air Canada flight attendants vote to strike if agreement not reached, union says
More than 10,000 flight attendants could strike later this month. Members voted 99% percent in favour to strike if a deal is not reached. A 72 hour strike notice could be issued as soon as Aug. 16 according to the union representing flight attendants.


Globe and Mail
an hour ago
- Globe and Mail
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.95 in the second quarter of 2025, up 13.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.3%. GAAP EPS for the quarter was $2.58, reflecting an uptick of 3.2% year over year. DaVita's Revenues in Detail Revenues of $3.38 billion in the second quarter increased 6.1% year over year. The figure topped the Zacks Consensus Estimate by 1.3%. Revenue per treatment in the second quarter of 2025 was $404.6 million, up 3.7% year over year and 1.1% sequentially. Per management, this was primarily driven by normal seasonal improvements, including patients meeting their co-insurance and deductibles. This was partially offset by decreased volume of phosphate binders. Shares of this company plunged nearly 10.1% till last trading. DVA's Segment Details DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.21 billion, up 4.8% year over year. Other revenues were $172.7 million, up 37.4% from the year-ago quarter's figure. Per management, the total U.S. dialysis treatments for the second quarter were 7,186,217 or 92,131 per day, on average. This represents a per-day increase of 0.4% on a sequential basis. Normalized non-acquired treatment declined 0.8% year over year in the second quarter of 2025. As of June 30, 2025, DaVita provided dialysis services to around 283,100 patients at 3,175 outpatient dialysis centers, of which 2,662 were U.S. centers while 513 were located across 13 other countries. During the second quarter of 2025, the company acquired one, opened three and closed two dialysis centers in the United States. It also opened six and closed five dialysis centers outside the United States in the same period. As of June 30, 2025, DaVita had approximately 64,400 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.3 billion in annualized medical spend. The company also had an additional 9,300 patients in other integrated care arrangements. DaVita's Margin Details In the quarter under review, DaVita's gross profit increased 7% year over year to $1.12 billion. The gross margin expanded 31 basis points (bps) to 33.1%. General & administrative expenses climbed 12.2% year over year to $412.8 million. Adjusted operating profit totaled $705.2 million, reflecting a 4.2% increase from the prior-year quarter's level. Adjusted operating margin in the second quarter contracted 36 bps to 20.9%. DVA's Financial Position DaVita exited second-quarter 2025 with cash and cash equivalents and short-term investments of $739.4 million compared with $511.9 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2025 was $10.26 billion compared with $9.74 billion at the first-quarter end. Cumulative net cash provided by operating activities at the end of second-quarter 2025 was $504.2 million compared with $664 million a year ago. During the three months ended June 30, 2025, DVA repurchased 3.1 million shares for $446 million. DaVita's Guidance DaVita has reiterated its adjusted EPS outlook for 2025. Adjusted EPS for the full year is continued to be projected in the range of $10.20-$11.30. The Zacks Consensus Estimate currently stands at $10.76. Our Take on DVA DaVita ended the second quarter of 2025 with better-than-expected results. The uptick in the company's top and bottom lines and revenue per treatment was encouraging. The per-day increase in total U.S. dialysis treatments for the second quarter on a sequential basis and solid revenues from both sources were encouraging. The opening and acquiring of dialysis centers within the United States and acquiring centers overseas were promising. The gross margin expansion bodes well for the stock. However, the year-over-year decline in normalized non-acquired treatment was disappointing. The contraction of the adjusted operating margin does not bode well for the stock. DaVita's Zacks Rank and Key Picks DVA currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC): Free Stock Analysis Report